August 20, 2021 07:47 AM EDT

While figuring out post-CRL future for roxadustat, FibroGen celebrates Europe OK with Astellas

Amber Tong

The FDA may not be ready to approve FibroGen’s roxadustat before it sees another clinical trial, but the European Commission is swinging its doors wide …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

While figuring out post-CRL future for roxadustat, FibroGen celebrates Europe OK with Astellas

Amber Tong

Sign up to read this article for free.

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

While fig­ur­ing out post-CRL fu­ture for rox­adu­s­tat, Fi­bro­Gen cel­e­brates Eu­rope OK with Astel­las

Amber Tong

Sign up to read this article for free.

more like this

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

While figuring out post-CRL future for roxadustat, FibroGen celebrates Europe OK with Astellas

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks